Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.
Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.